Nuvalent, Inc. (NUVL)
| Market Cap | 9.83B +71.9% |
| Revenue (ttm) | n/a |
| Net Income | -450.07M |
| EPS | -6.05 |
| Shares Out | 79.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,085,847 |
| Open | 123.97 |
| Previous Close | 123.94 |
| Day's Range | 123.95 - 123.99 |
| 52-Week Range | 71.13 - 123.99 |
| Beta | 1.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About NUVL
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of... [Read more]
Financial Performance
Financial StatementsNews
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Nuvalent Transcript: AGM 2026
The meeting, held virtually, covered director elections, executive compensation, and auditor ratification. All proposals passed, with final results to be filed in Form 8-K. Forward-looking statements were made with reference to risk factors in SEC filings.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZenec...
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p...
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can he...
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.
London's FTSE 100 falls as GSK slides after Nuvalent deal
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal ...
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of fin...
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Nuvalent Transcript: Jefferies Global Healthcare Conference 2026
The company is preparing for two major drug launches in 2024, with strong clinical data for neladalkib showing superior durability and tolerability compared to current standards. Physician and patient engagement is high, and global expansion is underway.
Nuvalent Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Two U.S. commercial launches are expected this year for ALK and ROS1 programs, with neladalkib showing strong durability and CNS activity in ALK patients. The pipeline includes ongoing pivotal trials and a HER2 program targeting CNS disease, with a new candidate to be announced by year-end.
Nuvalent Slides: Corporate presentation
Nuvalent has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026 Veteran biopha...
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA s...
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of Septe...
Nuvalent Earnings release: Q1 2026
Nuvalent released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Nuvalent Quarterly report: Q1 2026
Nuvalent has published its Q1 2026 quarterly earnings report on May 7, 2026.
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a...